Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia.
OBJECTIVE
This study was performed to determine the incidence of symptomatic, sustained atrial fibrillation in a group of patients with paroxysmal supraventricular tachycardia. The effects of the mechanism of paroxysmal supraventricular tachycardia (atrioventricular [AV] node reentry vs. AV reentry through an accessory pathway) and heart rate during the tachycardia on the occurrence of atrial fibrillation were also assessed.


BACKGROUND
There is a substantial incidence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia, but the precise incidence and the factors that determine it are unknown.


METHODS
One hundred sixty-nine patients with paroxysmal supraventricular tachycardia were followed up by regular clinic visits and transtelephonic electrocardiographic monitoring during symptomatic episodes of arrhythmia. The Kaplan-Meier product-limit method was used to estimate the proportion of patients remaining free of atrial fibrillation during the observation period. The Cox proportional hazards model was used to assess the effect of mechanism and heart rate during paroxysmal supraventricular tachycardia on the atrial fibrillation-free period.


RESULTS
Thirty-two (19%) of the 169 patients had an episode of atrial fibrillation during a mean follow-up period of 31 months. The cumulative percent of patients experiencing an episode of atrial fibrillation was 6% within 1 month, 9% within 4 months and 12% within 1 year. The mechanism of paroxysmal supraventricular tachycardia was not associated with the time to occurrence of atrial fibrillation; the hazard ratio corresponding to classification in the AV node reentry group was 0.8 (p > 0.6). The heart rate during paroxysmal supraventricular tachycardia was not associated with the time to occurrence of atrial fibrillation; the hazard ratio associated with an increase in heart rate of 50 beats/min during the tachycardia was 1.15 (p > 0.5).


CONCLUSIONS
This study suggests that atrial fibrillation will develop in approximately 12% of patients with paroxysmal supraventricular tachycardia during a 1-year follow-up period. The occurrence of atrial fibrillation is not related to the mechanism or heart rate of the paroxysmal supraventricular tachycardia.
Hamer
M E
ME
Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Division of Biometry, Duke University Medical Center, Durham, North Carolina.
Wilkinson
W E
WE
Clair
W K
WK
Page
R L
RL
McCarthy
E A
EA
Pritchett
E L
EL
D001281:Atrial Fibrillation / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology; D004562:Electrocardiography / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D015994:Incidence; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D016016:Proportional Hazards Models; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000503:physiopathology; D013614:Tachycardia, Paroxysmal / Q000150:complications* / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000150:complications* / Q000503:physiopathology; D013689:Telephone; D013997:Time Factors